Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Retained earnings is the accumulated portion of net income that is not distributed to shareholders. ResMed's retained earnings for the quarter that ended in Mar. 2026 was $6,959 Mil.
ResMed's quarterly retained earnings
increased
from Sep. 2025 ($6,342 Mil) to Dec. 2025 ($6,647 Mil) and
increased
from Dec. 2025 ($6,647 Mil) to Mar. 2026 ($6,959 Mil).
ResMed's annual retained earnings
increased
from Jun. 2023 ($4,253 Mil) to Jun. 2024 ($4,992 Mil) and
increased
from Jun. 2024 ($4,992 Mil) to Jun. 2025 ($6,081 Mil).
Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.
For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.
If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.
Of course, many companies with negative retained earnings have indeed lost money in the past.
Retained Earnings: Warren Buffett's Secret.
One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.
If the company loses more than it has accumulated, retained earnings is negative.
If a company isn't adding to its retained earnings, it isn't growing its net worth.
Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.
Microsoft is negative because it chose to buyback stock and pay dividends.
The more earnings retained, the faster it grows and increases growth rate for future earnings.
ResMed Retained Earnings Historical Data
* Premium members only.
The historical data trend for ResMed's Retained Earnings can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.
Of course, if a company loses, it is called retained losses, or accumulated losses.
ResMed (RSMDF) has a Retained Earnings of $6,959 Mil as of Mar. 2026. Retained earnings is the amount of net income not issued to shareholders. View historical data on ResMed and its competitors.
Is ResMed's Retained Earnings too high?
ResMed's current Retained Earnings is $6,959 Mil. Overall, ResMed has a GF Score™ of 96/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ResMed's Retained Earnings compare to MDLN and WST?
ResMed's Retained Earnings of $6,959 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Medical Devices & Instruments company?
A good Retained Earnings depends on the Medical Devices & Instruments industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on ResMed and its competitors. ResMed's current Retained Earnings is $6,959 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ResMed stock overvalued right now?
Based on GuruFocus' analysis, ResMed (RSMDF) is currently considered Significantly Undervalued. The stock's GF Value™ is $23.07, compared to a current price of $16.72 — trading 27.5% below its estimated fair value. The current Retained Earnings is $6,959 Mil. ResMed's overall GF Score™ is 96/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For ResMed (RSMDF), the current Retained Earnings is $6,959 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ResMed (RSMDF) Overvalued in 2026?
Based on GuruFocus' analysis, ResMed stock appears to be undervalued.
The current stock price of $16.72 is trading 27.5% below its estimated GF Value™ of $23.07.
GuruFocus considers ResMed to be Significantly Undervalued.
Key valuation signals for RSMDF:
Retained Earnings: $6,959 Mil
GF Value™: $23.07 vs. price of $16.72 (27.5% below fair value)
No single metric tells the full story. See the RSMDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with aging populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two-thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan, and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor, and payer in the out-of-hospital setting.
96GF Score
Get the complete analysis for RSMDF
Retained Earnings is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RSMDF has been successfully added to your 
